Markets
markets

Pfizer rises after earnings beat, boost to full-year profit outlook

Pfizer rose in premarket trading after it reported earnings results that beat Wall Street’s expectations and raised its full-year outlook.

The company reported adjusted earnings per share of $0.78, compared to the $0.58 analysts polled by FactSet were expecting. It also reported revenue of $14.7 billion, higher than the $13.4 billion the Street was penciling in.

Pfizer now expects full-year adjusted earnings per share to come in between $2.90 and $3.10, up from $2.80 to $3. The company held its annual revenue forecast of $61 billion to $64 billion.

Pfizer rose about 2% in premarket trading. The stock is down more than 10% this year as the patents on its more lucrative drugs are set to expire in the next couple years and its pipeline of new drugs has yet to excite investors.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.